Humanigen — KaloBios Pharmaceuticals — Investor Presentation (February 2017)
24 slides from Humanigen's investor presentation, Feb 15, 2017
Slide 1: Advancing Medicines for Neglected and Rare Diseases Through Innovative Business Models
Advancing Medicines for Neglected and Rare Diseases Through Innovative Business Models OTC: KBIO www.kalobios.com | Corporate Overview 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements | Corporate Overview 2 This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and ex
Slide 3: Compelling Investment Opportunity
Turnaround focused on high-value neglected and rare diseases, including pediatricPipeline with multiple potential near- and longer-term catalystsBenznidazole: expected 505(b)(2) development pathway for Chagas disease; possible PRVLenzilumab: recombinant mAb; possible PRVIfabotuzumab: recombinant mAb
Slide 4: Leadership
Leadership Cameron Durrant, MD, MBAChairman and CEOSenior pharmaceutical and biotech exec, turnaround specialistSenior exec roles at Pharmacia/Pfizer, J+J in US, Merck, GSK in Europe; experience as Exec Chairman, CEO and CFO; CEO roles at three specialty pharma groupsExpertise in anti-infectives, pe
Slide 5: Board of Directors
Board of Directors Cameron Durrant, MD, MBAChairman | Corporate Overview 5 Ronald Barliant, JDOf Counsel at Goldberg Kohn, extensive experience representing debtors and creditors in complex bankruptcy casesUnited States bankruptcy judge for the Northern District of Illinois 1988 to 2002Dale Chappell
Slide 6: Two-Pronged Value Model: a Unique Approach To Near-Term Return Propelling Long-Term Value Creation
Two-Pronged Value Model: a Unique Approach To Near-Term Return Propelling Long-Term Value Creation | Corporate Overview 6 Smart Investment in underappreciated assets Leverage FDA incentives for better efficiency Value Options From multiple FDA catalysts like PRV Value Creation Potential robust comme
Slide 7: Priority Review Vouchers (PRVs) Create Options For Significant Potential Return
Priority Review Vouchers (PRVs) Create Options For Significant Potential Return | Corporate Overview 7 Range of disclosed sale prices for PRVs is $67.5MM - $350MM Rare Pediatric Diseases (RPD) Neglected Tropical Diseases (NTD) Holder of PRV can receive priority review for any NDA/BLA PRV can be sold
Slide 8: KaloBios Turnaround Momentum Builds: Rising from the Ashes
| Corporate Overview 8 Funding dead-end, winding down Oct 2015 Martin Shkreli investment late Nov 2015 Shkreli arrest, indictment Dec 2015 Chapter 11 filing Dec 2015 Delisted by Nasdaq Jan 2016 Two new board members Jan 2016 New CEO Mar 2016 Announced Responsible Pricing Model April 2016 Exit from C
Slide 9: Current Pipeline
Current Pipeline | Corporate Overview 9 Pre-clin Phase I Phase II Phase III NDA/BLA Benznidazole (potential PRV)Chagas diseaseAnti-infective LenzilumabCMML Anti-GM-CSF mAb Lenzilumab (potential PRV)JMML (peds) – dependent on interim data in CMMLAnti-GM-CSF mAb Ifabotuzumab (potential PRV)Solid (peds
Slide 10: Benznidazole a potential treatment for Chagas disease
Benznidazole a potential treatment for Chagas disease | Corporate Overview 10
Slide 11: Chagas Disease
Neglected tropical disease presenting in the US and other nations On FDA list of NTDs eligible for PRVCurrently no FDA-approved treatmentsImmediate need for reliable benznidazole supply in US and abroad CHAGAS disease | Corporate Overview 11 Insect carries the parasite called Trypanosoma cruzi Infec
Slide 12: Benznidazole: the Preferred Treatment Globally for Chagas
Benznidazole: the Preferred Treatment Globally for Chagas | Corporate Overview 12 N N HN N
Slide 13: Benznidazole Strategy, Development Plan On Track
Benznidazole Strategy, Development Plan On Track | Corporate Overview 13 Positive FDA Guidance 505(b)(2) Pathway PRV Eligibility Confirmed Progress to Submission Received minutes from productive meeting Acceptable to FDAExpect no clinical efficacy or safety studies Currently expected to be eligible
Slide 14: Benznidazole Target Approval Plan
2016 2017 H1 H2 H1 H2 Manufacturing (CMC) Analytical methods development Drug substance Drug product Stability studies Non-Clinical (Non-Human) Metabolism / PK Toxicity assessment T.cruzi biology Environmental assessment Clinical Summary of relevant clinical studies Right of Reference & data extract
Slide 15: Lenzilumab a potential pipeline in a product
Lenzilumab a potential pipeline in a product | Corporate Overview 15
Slide 16: CMML overview
High unmet needPatients typically unsuitable for stem cell transplant40-90% patients show hypersensitivity to GM-CSF CMML overview | Corporate Overview 16 Recently classified as separate disease with distinct natural history* Median overall survival rate in months Newly diagnosed US patients per yea
Slide 17: JMML overview
No FDA-approved treatmentClear unmet needPotential for a rare pediatric disease PRVGM-CSF hypersensitivity is hallmarkPediatric oncology largely ignored in clinical development JMML overview | Corporate Overview 17 Event-free survival rate at 5 years (with bone marrow transplant) New US cases per ye
Slide 18: Lenzilumab is a Potent Inhibitor of GM-CSF Function In Vitro
Lenzilumab is a Potent Inhibitor of GM-CSF Function In Vitro | Corporate Overview 18 Inhibits GM-CSF-dependent Proliferation of Human TF-1 Leukemia Cells Blocks GM-CSF-induced STAT5 Phosphorylation in Human TF-1 Leukemia Cells Source: KaloBios laboratory notebook STAT5 phosphorylation detection in T
Slide 19: Lenzilumab: a Pipeline in a Drug Opportunity
Lenzilumab: a Pipeline in a Drug Opportunity | Corporate Overview 19 JMML ALPS / RALD Cytokine Release Syndrome AMML RASopathies (e.g. CFC syndrome, Costello syndrome) Noonan Syndrome with PTPN11 CMML CML Plexiform Neurofibroma Pediatric Multiple Sclerosis US ADDRESSABLE POPULATION 325 350 500 600 7
Slide 20: Ifabotuzumab potential for partnering and development
Ifabotuzumab potential for partnering and development | Corporate Overview 20
Slide 21: Ifabotuzumab Has Four Postulated Mechanisms of Action
1 2 3 4 Ifabotuzumab Has Four Postulated Mechanisms of Action | Corporate Overview 21 ADCC Mediated Killing of Tumor Cells Direct Apoptosis of Tumor Cells Disruption of Tumor Vasculature through Cell Rounding Anti-fibrotic Effect Ifabotuzumab Ifabotuzumab Ifabotuzumab Ifabotuzumab Humaneered® monocl
Slide 22: Capitalization Summary as of 2/14/17
Capitalization Summary as of 2/14/17 | Corporate Overview 22 Debt $4.3 million Common Shares Outstanding 14.9 million Stock Options (WAEP $5.82) 2.1 million Warrants (WAEP $14.24) 0.3 million Fully Diluted Shares Outstanding 17.3 million Note: share and per share amounts as of 9/30/16 – last 10-Q fi
Slide 23: Demonstrated History of Swift Execution in Challenging Circumstances
Demonstrated History of Swift Execution in Challenging Circumstances | Corporate Overview 23 JUN JUL AUG SEP DEC Emerge in six months from complex Chapter 11 bankruptcy Lenzilumab Phase 1 trial started Extinguished Martin Shkreli’s stake in the company Current with Securities and Exchange Commission
Slide 24: Summary
Summary Unique near-term/long-term potential value creation opportunity Thoughtful business strategy that leverages existing U.S. regulatory and development incentivesAttractive asset portfolio with multiple potential milestones and partnering prospectsDeeply focused new management team with an unwa
KaloBios Pharmaceuticals — Investor Presentation (February 2017) on 6ix